TG Therapeutics Inc (NASDAQ:TGTX) — Market Cap & Net Worth
Market Cap & Net Worth: TG Therapeutics Inc (TGTX)
TG Therapeutics Inc (NASDAQ:TGTX) has a market capitalization of $8.37 Billion ($8.37 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2555 globally and #930 in its home market, demonstrating a 0.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TG Therapeutics Inc's stock price $55.85 by its total outstanding shares 153083580 (153.08 Million). Also see TG Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
TG Therapeutics Inc Market Cap History: 2015 to 2026
TG Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.83 Billion to $8.55 Billion (14.16% CAGR). Also see cash flow conversion of TG Therapeutics Inc for how efficiently the company converts equity into cash flow.
Index Memberships
TG Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.31% | #59 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.02% | #295 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.42% | #20 of 602 |
Weight: TG Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TG Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TG Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TG Therapeutics Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.40x
TG Therapeutics Inc's market cap is 7.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.20x
TG Therapeutics Inc's market cap is 10.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $711.84 Million | $152.38K | -$78.25 Million | 4671.44x | N/A |
| 2017 | $1.26 Billion | $152.38K | -$118.48 Million | 8237.81x | N/A |
| 2018 | $627.64 Million | $152.00K | -$173.48 Million | 4129.23x | N/A |
| 2019 | $1.70 Billion | $152.00K | -$172.87 Million | 11179.13x | N/A |
| 2020 | $7.96 Billion | $152.00K | -$279.38 Million | 52390.84x | N/A |
| 2021 | $2.91 Billion | $6.69 Million | -$348.10 Million | 434.83x | N/A |
| 2022 | $1.81 Billion | $2.79 Million | -$223.81 Million | 650.26x | N/A |
| 2023 | $2.61 Billion | $233.66 Million | $12.67 Million | 11.19x | 206.33x |
| 2024 | $4.61 Billion | $329.00 Million | $23.38 Million | 14.01x | 197.06x |
| 2025 | $4.56 Billion | $616.29 Million | $447.18 Million | 7.40x | 10.20x |
Competitor Companies of TGTX by Market Capitalization
Companies near TG Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of TG Therapeutics Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to TG Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
TG Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, TG Therapeutics Inc's market cap moved from $1.83 Billion to $ 8.55 Billion, with a yearly change of 14.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.55 Billion | +87.35% |
| 2025 | $4.56 Billion | -0.96% |
| 2024 | $4.61 Billion | +76.23% |
| 2023 | $2.61 Billion | +44.38% |
| 2022 | $1.81 Billion | -37.74% |
| 2021 | $2.91 Billion | -63.48% |
| 2020 | $7.96 Billion | +368.65% |
| 2019 | $1.70 Billion | +170.73% |
| 2018 | $627.64 Million | -50.00% |
| 2017 | $1.26 Billion | +76.34% |
| 2016 | $711.84 Million | -61.02% |
| 2015 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of TG Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.37 Billion USD |
| MoneyControl | $8.37 Billion USD |
| MarketWatch | $8.37 Billion USD |
| marketcap.company | $8.37 Billion USD |
| Reuters | $8.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more